Iain McDougall

Publication Details

  • What is the role of 1100 MBq (<30 mCi) radioiodine I-131 in the treatment of patients with differentiated thyroid cancer? NUCLEAR MEDICINE COMMUNICATIONS VanWyngaarden, M., McDougall, I. R. 1996; 17 (3): 199-207

    Abstract:

    Based on pre-therapy whole-body 131I scintiscans showing only residual thyroid, 64 patients with differentiated thyroid cancer were treated with 1100 MBq ( < 30 mCi) 131I as out-patients. A follow-up whole-body scan with uptake measurements was made 6-12 months later. An uptake of 10%, this fell to 59%. A serum TSH > 10 microU ml-1 at the time of the first scan was associated with ablation (i.e. an uptake of < or = 0.3% on the follow-up scan) in 93% of patients. We recommend measurement of TSH and a whole-body scan to exclude regional or distant metastases, plus calculation of uptake in the neck to determine whether out-patient therapy with 1100 MBq is appropriate.

    View details for Web of Science ID A1996TZ72500005

    View details for PubMedID 8692486

Stanford Medicine Resources:

Footer Links: